|
EP1485127B1
(en)
|
2002-02-25 |
2011-06-08 |
Elan Pharmaceuticals, Inc. |
Administration of agents for the treatment of inflammation
|
|
US9415102B2
(en)
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
|
US20050271660A1
(en)
*
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
AU2003270330B2
(en)
*
|
2002-09-06 |
2009-07-30 |
Alexion Pharmaceuticals, Inc. |
Method of treatment of asthma using antibodies to complement component C5
|
|
EP1592440A4
(en)
*
|
2003-02-10 |
2007-07-11 |
Elan Pharm Inc |
IMMUNOGLOBULIN PREPARATION AND METHOD OF PRODUCING THE SAME
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
AU2005231822B2
(en)
*
|
2004-04-02 |
2011-07-21 |
Swedish Orphan Biovitrum Ab (Publ) |
Methods of reducing aggregation of IL-1ra
|
|
CA2478458A1
(en)
*
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
JP2008520717A
(ja)
*
|
2004-11-19 |
2008-06-19 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
多発性硬化症についての処置
|
|
PT2620450T
(pt)
*
|
2005-03-08 |
2018-12-17 |
Pfizer Prod Inc |
Composições de anticorpos anti-ctla-4
|
|
MX2007014148A
(es)
|
2005-05-19 |
2008-01-11 |
Amgen Inc |
Composiciones y metodos para incrementar la estabilidad de anticuerpos.
|
|
CN101309703A
(zh)
*
|
2005-09-12 |
2008-11-19 |
诺维莫尼公司 |
抗cd3抗体组合物
|
|
US9309316B2
(en)
|
2005-12-20 |
2016-04-12 |
Bristol-Myers Squibb Company |
Stable subcutaneous protein formulations and uses thereof
|
|
CN101389351B
(zh)
|
2005-12-29 |
2012-10-10 |
森托科尔公司 |
人抗il-23抗体、组合物、方法和用途
|
|
EP2359834B1
(en)
|
2006-03-15 |
2016-11-09 |
Alexion Pharmaceuticals, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
|
|
TW200806315A
(en)
*
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
AU2007300221A1
(en)
*
|
2006-09-25 |
2008-04-03 |
Medimmune, Llc. |
Stabilized antibody formulations and uses thereof
|
|
EP2081553B1
(en)
*
|
2006-10-06 |
2020-08-12 |
Amgen Inc. |
Stable antibody formulations
|
|
WO2008051363A2
(en)
|
2006-10-20 |
2008-05-02 |
Amgen Inc. |
Stable polypeptide formulations
|
|
CL2008000058A1
(es)
*
|
2007-01-09 |
2008-05-23 |
Wyeth Corp |
Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden.
|
|
ES2378094T3
(es)
*
|
2007-02-12 |
2012-04-04 |
Lassaad Boujbel |
Disolución de sucralosa estéril sin conservantes y su procedimiento de preparación
|
|
US20090208492A1
(en)
*
|
2007-06-14 |
2009-08-20 |
Elan Pharmaceuticals, Inc. |
Lyophilized Immunoglobulin Formulations and Methods of Preparation
|
|
BRPI0814252B8
(pt)
*
|
2007-06-14 |
2021-05-25 |
Biogen Idec Inc |
composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia
|
|
WO2009003010A2
(en)
*
|
2007-06-25 |
2008-12-31 |
Becton, Dickinson And Company |
Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
|
|
EP2201380B1
(en)
*
|
2007-10-22 |
2016-06-01 |
Becton Dickinson and Company |
Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
TWI532498B
(zh)
|
2008-03-17 |
2016-05-11 |
巴克斯特保健公司 |
供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
|
|
WO2009124294A2
(en)
*
|
2008-04-05 |
2009-10-08 |
Lpath, Inc. |
Pharmaceutical compositions for binding sphingosine-1-phosphate
|
|
CA2721037C
(en)
|
2008-04-15 |
2018-05-22 |
Talecris Biotherapeutics, Inc. |
Methods for preparing a concentrated plasma product formulation using ultrafiltration/diafiltration
|
|
AU2009288419B2
(en)
|
2008-08-27 |
2015-08-06 |
Merck Sharp & Dohme Llc |
Lyophilized formulatons of engineered anti-IL-23p19 antibodies
|
|
TWI516501B
(zh)
*
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Ｐｃｓｋ９拮抗劑類
|
|
KR20110096553A
(ko)
*
|
2008-11-28 |
2011-08-30 |
아보트 러보러터리즈 |
안정한 항체 조성물 및 이의 안정화 방법
|
|
KR101275413B1
(ko)
*
|
2008-12-29 |
2013-06-18 |
주식회사 삼양바이오팜 |
동결건조제형의 약제학적 조성물 및 그 제조방법
|
|
FR2940617B1
(fr)
*
|
2008-12-30 |
2012-04-20 |
Fractionnement Et Des Biotechonologies Lab Franc |
Composition d'immunoglobulines g
|
|
EP2419137A4
(en)
*
|
2009-04-17 |
2013-01-09 |
Biogen Idec Inc |
COMPOSITIONS AND METHOD FOR TREATING ACUTE MYELOGENIC LEUKEMIA
|
|
NZ613809A
(en)
*
|
2009-05-04 |
2015-02-27 |
Abbvie Biotechnology Ltd |
Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
|
|
EP2477603B1
(en)
*
|
2009-09-17 |
2016-03-30 |
Baxalta Incorporated |
Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
|
|
PL2485761T3
(pl)
*
|
2009-10-09 |
2019-10-31 |
Armagen Inc |
Sposoby i kompozycje do zwiększania aktywności 2-sulfatazy iduronianu w cns
|
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
|
CN107496917B
(zh)
|
2010-02-26 |
2021-06-11 |
诺沃—诺迪斯克有限公司 |
包含稳定抗体的组合物
|
|
NZ602676A
(en)
|
2010-04-16 |
2015-02-27 |
Biogen Ma Inc |
Anti-vla-4 antibodies
|
|
EP2575761B1
(en)
|
2010-05-28 |
2024-08-14 |
Novo Nordisk A/S |
Stable multi-dose compositions comprising an antibody and a preservative
|
|
DK3170508T3
(da)
|
2010-06-04 |
2020-01-02 |
Wyeth Llc |
Vaccineformuleringer
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP4289445A3
(en)
*
|
2010-09-17 |
2024-02-21 |
Takeda Pharmaceutical Company Limited |
Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph
|
|
DE19177059T1
(de)
|
2010-10-01 |
2021-10-07 |
Modernatx, Inc. |
N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
|
|
US20130337470A1
(en)
|
2010-10-25 |
2013-12-19 |
Biogen Idec Ma Inc. |
METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMadCAM LEVELS
|
|
PL2637690T3
(pl)
|
2010-11-11 |
2017-03-31 |
Abbvie Biotechnology Ltd |
Płynne formulacje zawierające przeciwciało anty-tnf alfa o wysokim stężeniu
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
SI2691112T1
(en)
|
2011-03-31 |
2018-07-31 |
Merck Sharp & Dohme Corp. |
STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
KR20140033171A
(ko)
*
|
2011-05-26 |
2014-03-17 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
비활성화된 뎅기 바이러스 백신
|
|
AU2012279205B2
(en)
|
2011-07-01 |
2017-08-31 |
Biogen Ma Inc. |
Arginine - free TNFR : Fc- fusion polypeptide compositions and methods of use
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
HUE057725T2
(hu)
|
2011-10-03 |
2022-06-28 |
Modernatx Inc |
Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása
|
|
HRP20220717T1
(hr)
|
2011-12-16 |
2022-07-22 |
Modernatx, Inc. |
Modificirani pripravci mrna
|
|
EA033387B1
(ru)
*
|
2012-01-23 |
2019-10-31 |
Regeneron Pharma |
СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2
|
|
EP4527855A3
(en)
*
|
2012-03-26 |
2025-06-11 |
Sanofi |
Stable igg4 based binding agent formulations
|
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
JP2015516143A
(ja)
|
2012-04-02 |
2015-06-08 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
|
|
US9303079B2
(en)
|
2012-04-02 |
2016-04-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
AR091902A1
(es)
|
2012-07-25 |
2015-03-11 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de un conjugado de insulina de accion prolongada
|
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
EP2727602A1
(en)
*
|
2012-10-31 |
2014-05-07 |
Takeda GmbH |
Method for preparation of a high concentration liquid formulation of an antibody
|
|
SMT202200337T1
(it)
|
2012-11-26 |
2022-09-14 |
Modernatx Inc |
Rna modificato al livello del terminale
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
PT3041513T
(pt)
|
2013-09-08 |
2020-09-07 |
Kodiak Sciences Inc |
Conjugados de polímeros zwiteriónicos com fator viii
|
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
WO2015051214A1
(en)
|
2013-10-03 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
US10617764B2
(en)
|
2013-11-21 |
2020-04-14 |
Genmab A/S |
Lyophilized anti-tissue factor antibody-drug conjugates
|
|
US9932591B2
(en)
|
2013-12-18 |
2018-04-03 |
University Of Delaware |
Reduction of lipase activity in product formulations
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
KR20210013299A
(ko)
|
2014-10-17 |
2021-02-03 |
코디악 사이언시스 인코포레이티드 |
부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
|
|
AR104847A1
(es)
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
|
US20210322549A1
(en)
*
|
2015-07-17 |
2021-10-21 |
Coherus Biosciences, Inc. |
Stable Aqueous Formulations of Natalizumab
|
|
US10484453B2
(en)
*
|
2015-07-29 |
2019-11-19 |
Xerox Corporation |
System and method for printing documents using print hardware and automatic context inference
|
|
CN108712911A
(zh)
|
2015-12-30 |
2018-10-26 |
科达制药股份有限公司 |
抗体及其缀合物
|
|
MX2018008300A
(es)
|
2016-01-13 |
2018-09-21 |
Genmab As |
Formulacion para anticuerpo y conjugado de farmaco del mismo.
|
|
ES2797298T3
(es)
|
2016-02-10 |
2020-12-01 |
Becton Dickinson France |
Procedimiento para evaluar la estabilidad de una formulación a base de proteína
|
|
WO2018091729A2
(en)
|
2016-11-21 |
2018-05-24 |
Zaklady Farmaceutyczne Polpharma Sa |
Aqueous pharmaceutical formulations
|
|
MX2019013072A
(es)
|
2017-05-02 |
2019-12-16 |
Merck Sharp & Dohme |
Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
EP3459527B1
(en)
*
|
2017-09-20 |
2022-11-23 |
Tillotts Pharma Ag |
Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
|
|
AU2018400751B2
(en)
|
2017-12-06 |
2022-07-21 |
Merck Sharp & Dohme Llc |
Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
|
MX2020005981A
(es)
*
|
2017-12-08 |
2020-08-24 |
Argenx Bvba |
Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada.
|
|
WO2019147824A1
(en)
|
2018-01-26 |
2019-08-01 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
|
|
WO2019169341A1
(en)
|
2018-03-02 |
2019-09-06 |
Kodiak Sciences Inc. |
Il-6 antibodies and fusion constructs and conjugates thereof
|
|
US20190269757A1
(en)
|
2018-03-05 |
2019-09-05 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
|
US11426446B2
(en)
|
2018-03-08 |
2022-08-30 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
EP3761953A1
(en)
|
2018-03-08 |
2021-01-13 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
TWI841554B
(zh)
|
2018-03-21 |
2024-05-11 |
丹麥商珍美寶股份有限公司 |
以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
|
|
WO2019198100A1
(en)
*
|
2018-04-10 |
2019-10-17 |
Dr. Reddy's Laboratories Limited |
Antibody formulation
|
|
JP2021521171A
(ja)
|
2018-04-10 |
2021-08-26 |
ドクター レディズ ラボラトリーズ リミテッド |
治療用抗体の安定な製剤
|
|
BR112020020741A2
(pt)
*
|
2018-04-10 |
2021-01-19 |
Dr. Reddy's Laboratories Limited |
Formulação farmacêutica estável de um anticorpo, e, formulação de anticorpo alfa4beta7 estável.
|
|
IL278522B2
(en)
|
2018-05-07 |
2025-10-01 |
Genmab As |
Methods for treating cancer with a combination of anti-PD-1 antibody and always an anti-tissue factor antibody drug
|
|
KR102848349B1
(ko)
|
2018-06-04 |
2025-08-21 |
바이오젠 엠에이 인코포레이티드 |
감소된 효과기 기능을 갖는 항-ｖｌａ-4 항체
|
|
MY209122A
(en)
|
2018-06-08 |
2025-06-23 |
argenx BV |
Compositions and methods for treating immune thrombocytopenia
|
|
US20230033021A1
(en)
|
2018-06-20 |
2023-02-02 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
|
WO2019246271A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
|
|
WO2019246313A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
|
US12171764B2
(en)
|
2018-06-20 |
2024-12-24 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
|
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
US12227565B2
(en)
|
2018-06-20 |
2025-02-18 |
Biora Therapeutics, Inc. |
Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
|
|
EP3811962A4
(en)
*
|
2018-06-25 |
2022-03-16 |
JCR Pharmaceuticals Co., Ltd. |
Protein-containing aqueous liquid formulation
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
|
|
AU2019377456A1
(en)
|
2018-11-07 |
2021-05-27 |
Merck Sharp & Dohme Llc |
Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
|
|
MA55149A
(fr)
|
2018-11-20 |
2021-09-29 |
Janssen Biotech Inc |
Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
|
|
GEAP202415690A
(en)
|
2018-12-19 |
2024-01-10 |
Merck Sharp & Dohme Llc |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
|
EP3903815A4
(en)
|
2018-12-24 |
2022-09-28 |
Grand Theravac Life Science (Nanjing) Co., Ltd. |
PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF HEPATITIS B, METHOD OF MANUFACTURE THEREOF AND USE THEREOF
|
|
MX2021014302A
(es)
|
2019-05-23 |
2022-01-04 |
Janssen Biotech Inc |
Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
|
|
CA3138072A1
(en)
*
|
2019-06-07 |
2020-12-10 |
Argenx Bvba |
Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration
|
|
AU2020291508A1
(en)
*
|
2019-06-11 |
2022-01-06 |
Macrogenics, Inc. |
Pharmaceutical formulations of bi-specific diabodies and use of the same
|
|
WO2021022249A1
(en)
*
|
2019-08-01 |
2021-02-04 |
Momenta Pharmaceuticals, Inc. |
Fcrn antibodies and methods of use thereof
|
|
WO2021050687A1
(en)
|
2019-09-10 |
2021-03-18 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
US11912784B2
(en)
|
2019-10-10 |
2024-02-27 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
WO2021124793A1
(ja)
*
|
2019-12-16 |
2021-06-24 |
ニプロ株式会社 |
凝集防止剤ならびにそれを用いた医薬組成物および医療用デバイス
|
|
DK4087875T3
(da)
|
2020-01-08 |
2024-10-28 |
argenx BV |
Antagonister af human neonatal Fc-receptor (FcRn) til behandling af pemphigus-sygdomme
|
|
US20230151102A1
(en)
*
|
2020-01-13 |
2023-05-18 |
Aptevo Research And Development Llc |
Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
|
|
EP4096802A4
(en)
*
|
2020-01-29 |
2024-07-03 |
Merck Sharp & Dohme LLC |
METHOD FOR SEPARATION OF HOST CELL LIPASES FROM ANTI-LAG3 ANTIBODY PRODUCTION
|
|
BR112022023489A2
(pt)
|
2020-05-21 |
2023-03-14 |
Janssen Biotech Inc |
Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
|
|
WO2022101935A1
(en)
*
|
2020-11-12 |
2022-05-19 |
Dr. Reddy’S Laboratories Limited |
Stable aqueous high concentration formulation of integrin antibody
|
|
US12122850B2
(en)
|
2022-03-14 |
2024-10-22 |
LamKap Bio gamma AG |
Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells
|
|
JP2025520431A
(ja)
|
2022-06-15 |
2025-07-03 |
アルジェニクス ビーブイ |
Ｆｃｒｎ／抗原結合分子及び使用方法
|
|
AU2024282654A1
(en)
|
2023-05-30 |
2025-12-04 |
Paragon Therapeutics, Inc. |
Alpha4beta7 integrin antibody compositions and methods of use
|